Patients Sue Genzyme Over Fabrazyme Rationing

Law360, New York (March 11, 2011, 1:57 PM EST) -- A group of patients slapped Genzyme Corp. with a putative national class action in Pennsylvania on Wednesday over the rationing plan it implemented for its enzyme replacement drug Fabrazyme after safety violations at its manufacturing plant forced it to cut production.

Matthew L. Kurzweg and C. Allen Black Jr. of Kurzweg Law Offices lodged the suit in the U.S. District Court for the Western District of Pennsylvania, alleging Genyzme's policy barring patients from receiving full recommended doses of Fabrazyme has caused them preventable and serious health...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

HOCHENDONER et al v. GENZYME CORPORATION et al


Case Number

2:11-cv-00313

Court

Pennsylvania Western

Nature of Suit

Other Statutory Actions

Judge

Arthur J. Schwab

Date Filed

March 9, 2011

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.